Jennifer Keating Litton, M.D., MHCM

Jennifer Keating Litton, M.D., MHCM, is a Professor at The University of Texas MD Anderson Cancer Center, where she specializes in breast oncology and cancer research. Her work focuses on therapeutic resistance mechanisms in triple-negative breast cancer, particularly PARP inhibitor resistance pathways involving BRN2-induced ATR/STAT3 signaling and FGFR3-mediated DNA repair. She has published landmark studies in Nature, PNAS, and the Journal of Clinical Investigation, including research on SARS-CoV-2 mRNA vaccine effects on tumor immune checkpoint blockade and deep learning models predicting neoadjuvant therapy responses. Her clinical interests encompass neoadjuvant systemic therapy optimization, radiation oncology's impact on tumor genomics, and sentinel lymph node biopsy decision-making.